iPSC
Stem cells produced by introducing specific transcription factors into somatic cells to reverse them to a pluripotent state. First reported by Shinya Yamanaka in 2006, they circumvent the ethical controversies surrounding embryonic stem cells and avoid immune rejection.
Timeline (last 90 days)
Any iPSC-based aging reversal therapy must pass long-term animal experiments and strict regulatory review before entering clinical trials, in order to balance efficacy and safety.
The traditional view holds that cells from elderly donors still retain part of their aging memory after reprogramming, such as epigenetic traces and mitochondrial functional damage.
The c-Myc used in the reprogramming process is a proto-oncogene, and its reactivation may promote abnormal cell proliferation, posing a tumorigenic risk.
If iPSC-derived cells are not fully differentiated after transplantation or undifferentiated cells remain, teratomas may form.
Researchers extracted cells from the blood of an 80-year-old donor and, through reprogramming, converted them into induced pluripotent stem cells (iPSCs), whose molecular age dropped to a level of less than 20 years old.
iPSC technology was first reported by Shinya Yamanaka in 2006, and the related transcription factors are called Yamanaka factors.
The key value of iPSCs lies in bypassing the ethical controversy of embryonic stem cells and in being obtainable from a patient's own cells, thereby avoiding immune rejection.
iPSCs have been used to build disease models, drug screening, and cell therapy.
There are currently two mainstream methods for transplanting human neurons: differentiating iPSCs into neural progenitor cells and injecting them into animal embryos or neonatal mouse brains, or implanting cerebral organoid fragments into animal brain regions.
iPSC technology can reverse-induce stem cells from a specific patient's skin or blood cells and then differentiate them into neurons, thereby reproducing that patient's genetic background in a living animal.
1 more timeline events
All Facts (12)
In 2006, Shinya Yamanaka discovered that introducing four transcription factors—Oct4, Sox2, Klf4, and c-Myc—into somatic cells can reprogram them into induced pluripotent stem cells (iPSC).
70%UnverifiedAny iPSC-based aging reversal therapy must pass long-term animal experiments and strict regulatory review before entering clinical trials, in order to balance efficacy and safety.
50%UnverifiedThe traditional view holds that cells from elderly donors still retain part of their aging memory after reprogramming, such as epigenetic traces and mitochondrial functional damage.
50%UnverifiedThe c-Myc used in the reprogramming process is a proto-oncogene, and its reactivation may promote abnormal cell proliferation, posing a tumorigenic risk.
50%UnverifiedIf iPSC-derived cells are not fully differentiated after transplantation or undifferentiated cells remain, teratomas may form.
50%UnverifiedResearchers extracted cells from the blood of an 80-year-old donor and, through reprogramming, converted them into induced pluripotent stem cells (iPSCs), whose molecular age dropped to a level of less than 20 years old.
50%UnverifiediPSC technology was first reported by Shinya Yamanaka in 2006, and the related transcription factors are called Yamanaka factors.
50%UnverifiedThe key value of iPSCs lies in bypassing the ethical controversy of embryonic stem cells and in being obtainable from a patient's own cells, thereby avoiding immune rejection.
50%UnverifiediPSCs have been used to build disease models, drug screening, and cell therapy.
50%UnverifiedThere are currently two mainstream methods for transplanting human neurons: differentiating iPSCs into neural progenitor cells and injecting them into animal embryos or neonatal mouse brains, or implanting cerebral organoid fragments into animal brain regions.
50%UnverifiediPSC technology can reverse-induce stem cells from a specific patient's skin or blood cells and then differentiate them into neurons, thereby reproducing that patient's genetic background in a living animal.
50%UnverifiedInduced pluripotent stem cells (iPSCs) are reprogrammed into a pluripotent state similar to embryonic stem cells by introducing specific transcription factors into adult cells, and then directionally differentiated into neural cells.
50%